MAIA Biotechnology, Inc. (MAIA)
1.325
+0.02
(+1.15%)
USD |
NYAM |
Sep 21, 16:00
1.33
0.00 (0.00%)
After-Hours: 20:00
MAIA Biotechnology Enterprise Value : 52.08M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 52.08M |
| September 17, 2026 | 57.55M |
| September 16, 2026 | 57.55M |
| September 15, 2026 | 53.90M |
| September 14, 2026 | 56.94M |
| September 11, 2026 | 51.47M |
| September 10, 2026 | 52.08M |
| September 09, 2026 | 53.29M |
| September 08, 2026 | 52.08M |
| September 04, 2026 | 52.68M |
| September 03, 2026 | 53.29M |
| September 02, 2026 | 55.72M |
| September 01, 2026 | 51.47M |
| August 31, 2026 | 52.08M |
| August 28, 2026 | 53.29M |
| August 27, 2026 | 56.33M |
| August 26, 2026 | 56.94M |
| August 25, 2026 | 58.16M |
| August 24, 2026 | 54.51M |
| August 21, 2026 | 56.94M |
| August 20, 2026 | 56.33M |
| August 19, 2026 | 56.94M |
| August 18, 2026 | 55.72M |
| August 17, 2026 | 56.94M |
| August 14, 2026 | 57.55M |
| Date | Value |
|---|---|
| August 13, 2026 | 53.90M |
| August 12, 2026 | 56.33M |
| August 11, 2026 | 56.33M |
| August 10, 2026 | 58.16M |
| August 07, 2026 | 58.76M |
| August 06, 2026 | 58.76M |
| August 05, 2026 | 57.55M |
| August 04, 2026 | 55.12M |
| August 03, 2026 | 52.68M |
| July 31, 2026 | 48.43M |
| July 30, 2026 | 48.43M |
| July 29, 2026 | 45.39M |
| July 28, 2026 | 47.82M |
| July 27, 2026 | 50.25M |
| July 24, 2026 | 47.82M |
| July 23, 2026 | 50.25M |
| July 22, 2026 | 51.47M |
| July 21, 2026 | 53.29M |
| July 20, 2026 | 50.25M |
| July 17, 2026 | 51.47M |
| July 16, 2026 | 53.29M |
| July 15, 2026 | 61.81M |
| July 14, 2026 | 59.98M |
| July 13, 2026 | 58.76M |
| July 10, 2026 | 59.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 75.86B |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.944M |
| Total Expenses (Quarterly) | 7.944M |
| EPS Diluted (Quarterly) | -0.1307 |
| Earnings Yield | -47.83% |
| Normalized Earnings Yield | -49.01 |